The veterinary-grade Gynostemma pentaphyllum powder supplied as Qiling Jiaogulan Powder is incorporated into dry feed premixes through a two-stage dispersion protocol rather than by direct addition to the total mixed ration. Its saponin-rich particle surface interacts with limestone and dicalcium phosphate carriers under low-shear mixing, causing electrostatic adhesion and uneven assay distribution when the mixer speed remains below 20 rpm during the first 60 seconds. A pre-blend with precipitated silica at 1:3 w/w is prepared in a 500 kg ribbon blender to reduce surface charging. The pre-blend is then extended with dried corncob granules or rice hulls to a final API concentration of 1.0–5.0 wt% before screening through a 500 μm rotary sifter. Sampling is performed at 10 points across the discharge zone, with in-house HPLC assay acceptance set at a relative standard deviation below 5.0%. The main downstream boundary is not palatability but saponin-induced foaming in rumen fluid. If a standardised extract containing 80% total gypenosides is incorporated above 0.3 wt% of the total mixed ration, rumen surface tension may fall sufficiently to alter gas bubble coalescence in grain-fed lambs. Published data for this specific veterinary-grade extract in rumen bloat is limited; the threshold is an in vitro screening value rather than a regulatory efficacy claim. Gynostemma pentaphyllum is not listed in the EU Register of Feed Additives under Regulation (EC) No 1831/2003, so EU feed premix use is confined to non-feed-additive veterinary frameworks or to third-country formulations with national registration. Each incoming lot is released against loss on drying, total gypenosides, heavy metals, and aflatoxin B1 before blending, with acceptance limits defined by the marketing authorization file.

What Changes in Wet Granulation When the API Is a Saponin-Rich Extract Rather Than a Purified Isolate?

The main difference is the formation of stabilised foam inside the binder solution and the collapse of low-density agglomerates during fluid-bed drying. For poultry water-soluble granules, the powder is formulated with maltodextrin, anhydrous citric acid, sodium bicarbonate, and povidone K30. The saponin fraction acts as an endogenous surfactant, lowering dynamic surface tension and stabilising fine air bubbles in the spray line. A vacuum-deaerated binder tank is operated at -0.8 bar absolute for 15 minutes before spraying to reduce nozzle blockage. Top-spray fluid-bed granulation is carried out at inlet air temperature 55–65 °C, product temperature 32–38 °C, and spray rate 80–120 g/min per kg of bed mass. The endpoint is reached when granules with a median particle size of 250–600 μm are formed and residual moisture after drying is below 3.5% w/w. Drying above 70 °C is avoided because gypenosides can darken and form sticky films on the distributor plate, causing channelling and non-uniform final moisture. Dissolution of the finished granules in water at 25 °C without stirring should produce complete dispersion within 120 seconds. If acidifiers are present, the effervescent reaction may generate a foam layer higher than 10 mm in a 250 mL beaker. This foam layer does not indicate loss of assay, but it must be controlled with 0.05% simethicone emulsion if automated nipple-drinker systems are sensitive to air locks.

Injectable-grade depyrogenation and hemolysis thresholds

Preparation of an injectable solution from Qiling Jiaogulan Powder is not a simple dissolution step. The API is extracted with cold water, clarified by centrifugation at 10,000 × g, and filtered sequentially through 0.45 μm and 0.22 μm membranes. The clarified solution is then concentrated by ultrafiltration with a 10 kDa molecular weight cut-off membrane to remove high-molecular-weight polysaccharides and endotoxin. The active phase may be adjusted to 0.1–0.5% w/v total gypenosides as stated in the specific marketing authorization. Sodium chloride is added to achieve isotonicity at 290–310 mOsm/kg. The pH is buffered to 6.0–7.4 with citrate or phosphate buffer; citrate is preferred because saponins may chelate divalent cations and form cloudy precipitates with calcium-containing tonicity agents. Haemolytic potential must be assessed before any intravenous route because dammarane-type saponins can disrupt erythrocyte membranes. An in vitro haemolysis test using washed ovine erythrocytes is included in batch release; a concentration producing less than 5.0% haemolysis after 60 minutes at 37 °C is considered non-haemolytic for intramuscular use, but intravenous safety requires a wider margin. Endotoxin content is controlled by the limulus amoebocyte lysate method with a limit below 0.5 EU/mL for large-volume parenterals. Subvisible particulate matter is checked per USP ⟨788⟩. If the solution cannot meet the subvisible particle limit, the formulation is switched to a sterile-filtered ampoule presentation rather than a multi-dose vial.

Oral solutions and drench formulations are compounded as preservative-challenged micellar systems rather than as simple aqueous dilutions. In a 100 L jacketed vessel, propylene glycol is charged first at 10–20% of final volume and the extract is dispersed under a high-shear rotor-stator mixer at 3,000 rpm for 20 minutes. Purified water is added under recirculation, followed by polysorbate 80 at 0.1–0.5% w/v and a preservative system containing sodium benzoate and potassium sorbate. The observed viscosity remains below 15 mPa·s at 20 °C, which is compatible with positive-displacement dosing pumps used in swine farrowing units. However, saponin micelles formed above the critical micelle concentration can reduce preservative efficacy by partitioning preservative molecules into the micellar phase. A preservative efficacy test according to USP ⟨51⟩ is therefore performed on the final container, not on a laboratory batch. Acceptance criteria for Gram-negative bacteria are tightened to a 3-log reduction at 14 days when the solution is packaged in multi-dose 5 L jerrycans with repeated opening under barn conditions. The solution must be protected from light because gypenosides undergo oxidative browning under ultraviolet exposure. Amber polyethylene terephthalate bottles or opaque high-density polyethylene containers are specified. The filling line is sanitised with 70% isopropanol at each shift change, and the first 20 L of each production campaign is discarded to reduce cross-contamination risk.

Hard gelatin capsule production from this extract requires moisture mapping rather than lubricant optimisation. The powder is not free-flowing because residual saponins and hygroscopic polysaccharides raise the moisture sorption capacity of the blend. A dry granulation step by slugging or roller compaction with pregelatinised starch, colloidal silicon dioxide, and magnesium stearate produces a granulate with a Hausner ratio between 1.20 and 1.30. The filling suite is maintained below 30% relative humidity because higher humidity causes the granulate to adhere to dosator pins and tamping pins, producing fill weight variation above 3.0%. Capsule shells are selected from low-moisture gelatin or hydroxypropyl methylcellulose grades to reduce shell embrittlement caused by the extract's residual moisture. Filling is carried out on a dosator machine at reduced speed relative to crystalline actives. Disintegration is checked in 0.1 N HCl at 37 °C per USP ⟨701⟩; complete disintegration should occur within 15 minutes for uncoated hard capsules. Batch-to-batch variation in total gypenosides affects the angle of repose and the granulate bulk density, so the extract is pre-blended with the filler to a target assay of 95–105% of the label claim before final lubrication.

When Direct Compression Is Selected for Companion Animal Tablets, Particle Size Governs Capping

The extract is not suitable for direct compression without dry granulation because residual saponins and hygroscopic polysaccharides raise the moisture sorption capacity of the blend. Dry granulation by slugging or roller compaction with microcrystalline cellulose, dibasic calcium phosphate dihydrate, crospovidone, and magnesium stearate produces a granulate with a Hausner ratio between 1.20 and 1.30. Tablets containing 100 mg or 200 mg of the extract are compressed on a 16-station rotary press at a compression force of 8–15 kN and a turret speed of 25–35 rpm. Friability remains below 1.0% when the granules contain not more than 0.5% w/w magnesium stearate and when residual moisture is held at 2.5–4.0% w/w. If the moisture falls below 2.0% w/w, the tablets develop capping at the upper punch face because the elastic recovery of the dammarane-rich particles exceeds the plastic deformation of the dibasic calcium phosphate filler. If the moisture rises above 4.5% w/w, the powder sticks to the die table and punch tips. Hardness is measured per USP ⟨1217⟩, and disintegration is checked in 0.1 N HCl at 37 °C with discs. Complete disintegration occurs within 15 minutes for uncoated tablets; coated tablets require a 45-minute limit under the same conditions. Batch-to-batch variation in total gypenosides affects tablet hardness, so the extract is pre-blended with the filler to a target assay of 95–105% of the label claim before final lubrication.

Twin-screw wet granulation of high-saponin equine granules requires post-extrusion moisture profiling

For equine oral granules, high-dose administration is limited by powder palatability and by the risk of oesophageal impaction in horses. A twin-screw wet granulation line with a 16 mm screw diameter and a length-to-diameter ratio of 40:1 is used to densify the extract without over-wetting. The extruded mass is pressed through a 1.0 mm screen and spheronised at 800 rpm for 90 seconds to produce pellets with a particle size distribution between 710 μm and 1,400 μm. The granulation liquid is a 5.0% w/w maltodextrin solution containing 0.05% w/w polysorbate 80 to lower surface tension and reduce torque fluctuation. The moisture profile after extrusion is measured at three positions across the screw barrel outlet: centre, edge, and residual heel. A difference greater than 1.5% w/w between centre and edge samples indicates inadequate distribution of the granulation liquid and produces bimodal particle size. The wet granules are dried in a fluid-bed dryer at 50–60 °C until a final moisture of 3.0–5.0% w/w is reached. The product is packed in moisture-barrier foil pouches. Silica gel desiccant is not added because it can strip moisture too rapidly and cause brittle fracture of the granules during transport. No specific pharmacopoeial monograph governs Gynostemma-containing equine granules; stability is evaluated according to VICH GL3 or the equivalent regional guidance for the target market.